Literature DB >> 32646850

Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial.

Francesco Giganti1, Clare Allen2, Mark Emberton3, Caroline M Moore3, Veeru Kasivisvanathan3.   

Abstract

The PRECISION trial was a multicentre randomised study that demonstrated that multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy is superior to standard transrectal ultrasound-guided biopsy for the detection of prostate cancer. The outcomes of studies reporting mpMRI-targeted biopsies are dependent on the quality of the mpMRI but there are currently no scoring systems available for evaluating this. We introduced a novel scoring system, the Prostate Imaging Quality (PI-QUAL) score, to assess the quality of scans in the PRECISION trial. PI-QUAL is a score on a Likert scale from 1 to 5, where 1 means that no mpMRI sequences are of diagnostic quality and 5 implies that each sequence is independently of optimal diagnostic quality. Fifty-eight out of 252 (23%) mpMRI scans chosen at random from each of the 22 centres in this trial were evaluated by two experienced radiologists from the coordinating trial centre, in consensus, blinded to pathology results. Overall, the mpMRI quality in the centres participating in PRECISION was good. MpMRI quality was of sufficient diagnostic quality (PI-QUAL ≥3) for 55 scans (95%) and of good or optimal diagnostic quality (PI-QUAL ≥4) for 35 scans (60%). Fifty-five out of 58 (95%) scans were of diagnostic quality for T2WI, followed by DWI (46/58 scans; 79%), and DCE (38/58 scans; 66%). Further validation of this scoring system is warranted. PATIENT
SUMMARY: In this study we developed a scoring system (PI-QUAL) to assess the quality of multiparametric magnetic resonance imaging (mpMRI) in prostate cancer detection. We used scans from 22 centres that participated in the PRECISION trial. Although there was room for improvement in images that used intravenous contrast, we found that mpMRI in the PRECISION trial was of sufficient diagnostic quality (PI-QUAL score ≥3) for 95% of the scans.
Copyright © 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Magnetic resonance imaging: Quality control; Prostate cancer; Scoring system

Mesh:

Year:  2020        PMID: 32646850     DOI: 10.1016/j.euo.2020.06.007

Source DB:  PubMed          Journal:  Eur Urol Oncol        ISSN: 2588-9311


  27 in total

Review 1.  [Machine learning and multiparametric MRI for early diagnosis of prostate cancer].

Authors:  D Bonekamp; H-P Schlemmer
Journal:  Urologe A       Date:  2021-03-12       Impact factor: 0.639

2.  MRI as a screening tool for prostate cancer: current evidence and future challenges.

Authors:  Christoph Würnschimmel; Thenappan Chandrasekar; Luisa Hahn; Tarik Esen; Shahrokh F Shariat; Derya Tilki
Journal:  World J Urol       Date:  2022-02-28       Impact factor: 4.226

Review 3.  Deep learning-based artificial intelligence applications in prostate MRI: brief summary.

Authors:  Baris Turkbey; Masoom A Haider
Journal:  Br J Radiol       Date:  2021-12-03       Impact factor: 3.039

Review 4.  Emerging MR methods for improved diagnosis of prostate cancer by multiparametric MRI.

Authors:  Durgesh Kumar Dwivedi; Naranamangalam R Jagannathan
Journal:  MAGMA       Date:  2022-07-22       Impact factor: 2.533

Review 5.  Imaging quality and prostate MR: it is time to improve.

Authors:  Francesco Giganti; Clare Allen
Journal:  Br J Radiol       Date:  2020-11-11       Impact factor: 3.039

Review 6.  Quality in MR reporting (include improvements in acquisition using AI).

Authors:  Liang Wang; Daniel J Margolis; Min Chen; Xinming Zhao; Qiubai Li; Zhenghan Yang; Jie Tian; Zhenchang Wang
Journal:  Br J Radiol       Date:  2022-02-04       Impact factor: 3.039

7.  Better Image Quality for Diffusion-weighted MRI of the Prostate Using Deep Learning.

Authors:  Baris Turkbey
Journal:  Radiology       Date:  2022-02-01       Impact factor: 11.105

8.  Value of bowel preparation techniques for prostate MRI: a preliminary study.

Authors:  Cynthia Schmidt; Andreas M Hötker; Urs J Muehlematter; Irene A Burger; Olivio F Donati; Borna K Barth
Journal:  Abdom Radiol (NY)       Date:  2021-03-26

Review 9.  Challenges and opportunities for artificial intelligence in oncological imaging.

Authors:  H M C Cheung; D Rubin
Journal:  Clin Radiol       Date:  2021-04-24       Impact factor: 3.389

10.  Selecting Patients with Favorable Risk, Grade Group 2 Prostate Cancer for Active Surveillance-Does Magnetic Resonance Imaging Have a Role?

Authors:  T Stonier; A L Tin; D D Sjoberg; G Jibara; A J Vickers; S Fine; J Eastham
Journal:  J Urol       Date:  2020-11-20       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.